person · Reporting owner

FOUSE JACQUALYN A

Disclosed activity across 5 companies

Tapewire entity: 35960
SEC CIK: 0001405288

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499	Director	June 18, 2026	June 23, 2026
CELGENE CORP /DE/CELG · Entity 15781	Director · see remarks	February 14, 2017	February 16, 2017
DICK'S SPORTING GOODS, INC.DKS · Entity 556	Director	March 22, 2020	March 24, 2020
INCYTE CORPINCY · Entity 3182	Director	June 08, 2026	June 10, 2026
MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441	Director	June 17, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGIOS PHARMACEUTICALS, INC.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	154,156	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 154,156
Restricted stock unitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Restricted stock unitsSEC Table II · derivative / convertible security	Direct	2,927	Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18	Direct	14,950	Reported balance After 2026-06-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

CELGENE CORP /DE/

Report date February 14, 2017 · Filed February 16, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	16,322	Reported balance After 2017-02-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-02-14 · Grant · Acquired 16,322 · Balance 16,322 F1: Each share of phantom stock represents a right to receive one share of common stock. F3: The reporting person was awarded 16,322 shares of common stock pursuant to the 2014-2016 Long Term Incentive Plan under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). The reporting person deferred the receipt of such 16,322 shares of common stock and received instead 16,322 shares of phantom stock pursuant to the Celgene Corporation 2005 Deferred Compensation Plan. F2: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of phantom stock represents a right to receive one share of common stock.

F2: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation.

F3: The reporting person was awarded 16,322 shares of common stock pursuant to the 2014-2016 Long Term Incentive Plan under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). The reporting person deferred the receipt of such 16,322 shares of common stock and received instead 16,322 shares of phantom stock pursuant to the Celgene Corporation 2005 Deferred Compensation Plan.

DICK'S SPORTING GOODS, INC.

Report date March 22, 2020 · Filed March 24, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivative	Direct	55,288	Reported balance After 2020-03-22 transaction · row 1 1 source row Row 1 · 2020-03-22 · Grant · Acquired 9,518 · Balance 55,288 F1: Shares of time-based restricted stock, subject to vesting.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of time-based restricted stock, subject to vesting.

INCYTE CORP

Report date June 08, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,968	Reported balance After 2026-06-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 20,968 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07	Direct	6,111	Reported balance After 2026-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Filing footnotes · ownership attribution and instrument terms

F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

MADRIGAL PHARMACEUTICALS, INC.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,551	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 454 · Balance 1,551 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17	Direct	766	Reported balance After 2026-06-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 18, 2026 Filed Jun 23, 2026 21:22 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	14,950	$0.00 Strike: $34.16	$0.00	Disclosure SEC source: 0001439222-26-000101 · wk-form4_1782249776.xml · derivative · entry 4 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:22 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	2,927	$0.00	$0.00	Disclosure SEC source: 0001439222-26-000101 · wk-form4_1782249776.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:22 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	2,816	$0.00	$0.00	Disclosure SEC source: 0001439222-26-000101 · wk-form4_1782249776.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:22 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	2,816	$0.00	$0.00	Disclosure SEC source: 0001439222-26-000101 · wk-form4_1782249776.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 17, 2026 Filed Jun 18, 2026 20:19 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantStock Option (Right to Buy) · Derivative	766	$0.00 Strike: $499.86	$0.00	Disclosure SEC source: 0001628280-26-044325 · wk-form4_1781813955.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766 Underlying: Common Stock · 766 shares Expires 2036-06-17 F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document
June 17, 2026 Filed Jun 18, 2026 20:19 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantCommon Stock	454	$0.00	$0.00	Disclosure SEC source: 0001628280-26-044325 · wk-form4_1781813955.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,551 F1 · kind: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document
June 08, 2026 Filed Jun 10, 2026 20:07 UTC	INCYTE CORP INCY · Entity 3182	GrantNon Qualfied Stock Option (right to buy) · Derivative	6,111	$0.00 Strike: $100.64	$0.00	Disclosure SEC source: 0001405288-26-000006 · wk-form4_1781122043.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,111 Underlying: Common Stock · 6,111 shares Expires 2036-06-07 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 08, 2026 Filed Jun 10, 2026 20:07 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,642	$0.00	$0.00	Disclosure SEC source: 0001405288-26-000006 · wk-form4_1781122043.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,968 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:23 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	2,120	$0.00	$0.00	Disclosure SEC source: 0001439222-25-000055 · wk-form4_1750710197.xml · derivative · entry 4 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:23 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	2,120	$0.00	$0.00	Disclosure SEC source: 0001439222-25-000055 · wk-form4_1750710197.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 20, 2025 Filed Jun 24, 2025 20:39 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantStock Option (Right to Buy) · Derivative	366	$0.00 Strike: $285.73	$0.00	Disclosure SEC source: 0001628280-25-032855 · wk-form4_1750797581.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366 Underlying: Common Stock · 366 shares Expires 2035-06-20 F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date. Read SEC document
June 20, 2025 Filed Jun 24, 2025 20:39 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantCommon Stock	203	$0.00	$0.00	Disclosure SEC source: 0001628280-25-032855 · wk-form4_1750797581.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,097 F1 · kind: Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:23 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	15,768	$0.00 Strike: $35.50	$0.00	Disclosure SEC source: 0001439222-25-000055 · wk-form4_1750710197.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,768 Underlying: Common stock · 15,768 shares Expires 2035-06-18 F3 · derivative.exercise_date: These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026. Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:23 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	2,816	$0.00	$0.00	Disclosure SEC source: 0001439222-25-000055 · wk-form4_1750710197.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,816 Underlying: Common stock · 2,816 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:30 UTC	INCYTE CORP INCY · Entity 3182	GrantNon Qualfied Stock Option (right to buy) · Derivative	9,216	$0.00 Strike: $70.07	$0.00	Disclosure SEC source: 0001628280-25-031013 · wk-form4_1749760237.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,216 Underlying: Common Stock · 9,216 shares Expires 2035-06-09 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:30 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,518	$0.00	$0.00	Disclosure SEC source: 0001628280-25-031013 · wk-form4_1749760237.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,326 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
April 10, 2025 Filed Apr 10, 2025 20:02 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	SaleCommon stock	7,497	$25.90	$194,172.30	Disclosure SEC source: 0001439222-25-000029 · wk-form4_1744315371.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,220 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated April 8, 2022. Read SEC document
April 08, 2025 Filed Apr 10, 2025 20:02 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	15,933	$0.00	$0.00	Disclosure SEC source: 0001439222-25-000029 · wk-form4_1744315371.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 15,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document
April 08, 2025 Filed Apr 10, 2025 20:02 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	15,933	$0.00	$0.00	Disclosure SEC source: 0001439222-25-000029 · wk-form4_1744315371.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 10, 2025 Filed Mar 12, 2025 20:29 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantStock Option (Right to Buy) · Derivative	1,579	$0.00 Strike: $329.16	$0.00	Disclosure SEC source: 0001628280-25-012364 · wk-form4_1741811339.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,579 Underlying: Common Stock · 1,579 shares Expires 2035-03-10 F2 · derivative.exercise_date: The option vests as to 50% of the shares on the first anniversary of the date of grant (March 10, 2026) and, thereafter, 12.5% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document
March 10, 2025 Filed Mar 12, 2025 20:29 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantCommon Stock	894	$0.00	$0.00	Disclosure SEC source: 0001628280-25-012364 · wk-form4_1741811339.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894 F1 · kind: Represents a grant of restricted stock units, which vest as to 50% of the shares on each of March 10, 2026 and March 10, 2027, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document
June 20, 2024 Filed Jun 24, 2024 20:10 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	11,774	$0.00 Strike: $42.45	$0.00	Disclosure SEC source: 0001439222-24-000109 · wk-form4_1719259849.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,774 Underlying: Common stock · 11,774 shares Expires 2034-06-20 F3 · derivative.exercise_date: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025. Read SEC document
June 20, 2024 Filed Jun 24, 2024 20:10 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	2,120	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000109 · wk-form4_1719259849.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,120 Underlying: Common stock · 2,120 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 13, 2024 Filed Jun 17, 2024 21:31 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	3,388	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000089 · wk-form4_1718659858.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 13, 2024 Filed Jun 17, 2024 21:31 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	3,388	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000089 · wk-form4_1718659858.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 12, 2024 Filed Jun 14, 2024 16:16 UTC	INCYTE CORP INCY · Entity 3182	GrantNon Qualfied Stock Option (right to buy) · Derivative	12,517	$0.00 Strike: $59.94	$0.00	Disclosure SEC source: 0000879169-24-000096 · wk-form4_1718381801.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,517 Underlying: Common Stock · 12,517 shares Expires 2034-06-11 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 12, 2024 Filed Jun 14, 2024 16:16 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,830	$0.00	$0.00	Disclosure SEC source: 0000879169-24-000096 · wk-form4_1718381801.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,808 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
April 10, 2024 Filed Apr 10, 2024 20:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	SaleCommon stock	7,791	$27.55	$214,642.05	Disclosure SEC source: 0001439222-24-000063 · wk-form4_1712779426.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,396 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated April 8, 2022. Read SEC document
April 08, 2024 Filed Apr 10, 2024 20:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	15,934	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000063 · wk-form4_1712779426.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,933 Underlying: Common stock · 15,934 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document
April 08, 2024 Filed Apr 10, 2024 20:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	15,934	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000063 · wk-form4_1712779426.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 24, 2024 Filed Jan 24, 2024 21:22 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	SaleCommon stock	10,722	$21.64	$232,024.08	Disclosure SEC source: 0001439222-24-000016 · wk-form4_1706131320.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,253 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated April 8, 2022. Read SEC document
January 20, 2024 Filed Jan 24, 2024 21:22 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionPerformance share units · Derivative	23,900	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000016 · wk-form4_1706131320.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 23,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on April 8, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on April 8, 2022. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
January 20, 2024 Filed Jan 24, 2024 21:22 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	23,900	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000016 · wk-form4_1706131320.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 09, 2024 Filed Jan 9, 2024 21:26 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	SaleCommon stock	8,391	$22.99	$192,909.09	Disclosure SEC source: 0001439222-24-000008 · wk-form4_1704835604.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,075 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated February 10, 2021. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:26 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionPerformance share units · Derivative	17,500	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000008 · wk-form4_1704835604.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on February 10, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on February 10, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
January 05, 2024 Filed Jan 9, 2024 21:26 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	17,500	$0.00	$0.00	Disclosure SEC source: 0001439222-24-000008 · wk-form4_1704835604.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 30, 2023 Filed Jun 30, 2023 20:07 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	SaleCommon stock	10,718	$28.36	$303,962.48	Disclosure SEC source: 0001439222-23-000107 · wk-form4_1688155663.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,966 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. Read SEC document
June 28, 2023 Filed Jun 30, 2023 20:07 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionPerformance share units · Derivative	23,900	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000107 · wk-form4_1688155663.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,900 Underlying: Common stock · 23,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
June 28, 2023 Filed Jun 30, 2023 20:07 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	23,900	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000107 · wk-form4_1688155663.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 14, 2023 Filed Jun 16, 2023 20:00 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	11,294	$0.00 Strike: $61.44	$0.00	Disclosure SEC source: 0001209191-23-037797 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,294 Underlying: Common Stock · 11,294 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 14, 2023 Filed Jun 16, 2023 20:00 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,505	$0.00	$0.00	Disclosure SEC source: 0001209191-23-037797 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,978 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
June 13, 2023 Filed Jun 15, 2023 20:29 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantStock options (right to buy) · Derivative	18,958	$0.00 Strike: $26.56	$0.00	Disclosure SEC source: 0001439222-23-000085 · wk-form4_1686860968.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,958 Underlying: Common stock · 18,958 shares Expires 2033-06-13 F3 · derivative.exercise_date: This option was granted on June 13, 2023. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2024. Read SEC document
June 13, 2023 Filed Jun 15, 2023 20:29 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	GrantRestricted stock units · Derivative	3,388	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000085 · wk-form4_1686860968.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,388 Underlying: Common stock · 3,388 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document
April 12, 2023 Filed Apr 12, 2023 20:17 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Tax withholdingCommon stock	4,731	$21.35	$101,006.85	Disclosure SEC source: 0001439222-23-000059 · wf-form4_168133063686204.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,784 Read SEC document
April 08, 2023 Filed Apr 12, 2023 20:17 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	15,933	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000059 · wf-form4_168133063686204.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,867 Underlying: Common stock · 15,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document
April 08, 2023 Filed Apr 12, 2023 20:17 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	15,933	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000059 · wf-form4_168133063686204.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2023 Filed Feb 16, 2023 21:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Tax withholdingCommon stock	3,648	$28.91	$105,463.68	Disclosure SEC source: 0001439222-23-000024 · wf-form4_167658141141317.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,582 Read SEC document
February 14, 2023 Filed Feb 16, 2023 21:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionRestricted stock units · Derivative	11,333	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000024 · wf-form4_167658141141317.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 11,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document
February 14, 2023 Filed Feb 16, 2023 21:03 UTC	AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499	Exercise / conversionCommon stock	11,333	$0.00	$0.00	Disclosure SEC source: 0001439222-23-000024 · wf-form4_167658141141317.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 30, 2022 Filed Jan 4, 2023 21:02 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	252	$80.32	$20,240.64	Disclosure SEC source: 0001209191-23-000801 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,473 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.